ada standards of care 2025 obesity pharmacotherapy glp-1 Your Guide to the 2025 ADA Diabetes Care Updates

M., & Van Raalte, D

Several studies have demonstrated that the GLP-1 receptor agonists such as extendin-4 and liraglutide can activate AMPK signalling in multiple tissues and cell types, including cardiomyocyte hyperglycaemic [20] or cardiac hypertrophy models [21], in rat INS-1 pancreatic beta cells [22], and in L6 myotubes, resulting in the sensitisation of insulin-stimulated glucose uptake [23]

Its easy to pass judgment on topics we dont fully understand, people we cant empathize with, or, more commonly in this case, feel jealous towards

However, patients must initiate the conversation with their doctor, which may present a barrier if they lack an established relationship or if their provider is unfamiliar with GLP-1 compounding